EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)ÄquivalenzstudieRandomisierte kontrollierte Studie

Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers

Pan Luo, Yongfang Lei, Chang Liu, Juan Du, Xiangxiao Deng, Hengyi Yu, Xingxing Qi, Zheng He, Dongling Zhang, Qin Zuo, Yinian Fang, Dong Liu und 2 weitere

Clinical Pharmacology in Drug Development · 2026-04 · 15 (4)

DOI: 10.1002/cpdd.70058 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 10.04.2026. Verfasst von Pan Luo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antifungal Agents, Drugs, Generic, Voriconazole. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Wuhan Qirui Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voriconazole is a broad‐spectrum antifungal agent belonging to the triazole class, exhibiting significant efficacy against a diverse array of pathogenic organisms. This study aimed to assess the pharmacokinetic properties, bioequivalence, and safety profiles of two oral formulations of voriconazole tablets. An open‐label, randomized, two‐period, two‐sequence crossover, Phase I bioequivalence trial was conducted involving healthy Chinese volunteers under fasting conditions. During each study period, participants were administered a single 200 mg dose of either the generic (test) or branded (reference) voriconazole tablet, with treatment sequences assigned randomly. Blood samples were collected at various time points before and after administration to determine plasma voriconazole concentrations. The study assessed bioequivalence by calculating the maximum concentration (C max ) and the area under the concentration–time curve (AUC). Adverse events (AEs) were systematically documented. A total of seventy healthy volunteers were recruited, with 68 participants who received voriconazole included in the final analysis. The geometric mean ratios (GMR) of the test tablet to the reference for C max , the area under the concentration curve from time 0 to the last measurable time point (AUC 0–t ), and the area under the concentration curve from time 0 extrapolated to infinity (AUC 0–inf ) were determined to be 1.03, 0.98, and 0.97, respectively, under fasting conditions. These values met the established criteria for bioequivalence acceptance. Furthermore, both the test and reference formulations of voriconazole were well tolerated. The findings indicate that the test and reference voriconazole tablets are bioequivalent and possess similar safety profiles in healthy Chinese volunteers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsDrugs, GenericVoriconazoleAdolescentAdultFemaleHumansMaleYoung AdultAdministration, OralArea Under CurveChinaCross-Over StudiesHealthy VolunteersTabletsTherapeutic Equivalency

Stichwörter der Autor:innen

bioequivalencepharmacokineticssafetyvoriconazole

Substanzen

Antifungal AgentsDrugs, GenericTabletsVoriconazole

Autor:innen und Institutionen

  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Clinical Pharmacology, Wuhan Createrna Science and Technology Co., Ltd., Wuhan, China.

Förderung

  • Wuhan Qirui Pharmaceutical Co., Ltd

Zitieren

APA

Luo, P., Lei, Y., Liu, C., Du, J., Deng, X., Yu, H., Qi, X., He, Z., Zhang, D., Zuo, Q., Fang, Y., Liu, D., Chen, Q., & Ren, X. (2026). Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development, 15(4). https://doi.org/10.1002/cpdd.70058

Vancouver

Luo P, Lei Y, Liu C, Du J, Deng X, Yu H, et al. Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development. 2026;15(4). doi:10.1002/cpdd.70058

BibTeX
@article{Luo2026,
  author = {Luo, Pan and Lei, Yongfang and Liu, Chang and Du, Juan and Deng, Xiangxiao and Yu, Hengyi and Qi, Xingxing and He, Zheng and Zhang, Dongling and Zuo, Qin and Fang, Yinian and Liu, Dong and Chen, Qian and Ren, Xiuhua},
  title = {Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cpdd.70058}
}
Kostenlos starten →